◀ Back to MAPK3
AGT — MAPK3
Pathways - manually collected, often from reviews:
-
BioCarta role of ß-arrestins in the activation and targeting of map kinases:
Ligand/GPCR(+)/Arrestin/RAF1/MEK1/MEK2/ERK1/ERK2 complex (CCL4_EDN1__AGT_CCL11_CXCL12_F2_compound:CAS66575-29-9_compound:CAS745-65-3-ARRB1-RAF1-MAP2K1-MAP2K2-MAPK3-MAPK1)
→
MEK2 (MAP2K2)
(modification, collaborate)
-
BioCarta role of ß-arrestins in the activation and targeting of map kinases:
Ligand/GPCR(+)/Arrestin/RAF1/MEK1/MEK2/ERK1/ERK2 complex (CCL4_EDN1__AGT_CCL11_CXCL12_F2_compound:CAS66575-29-9_compound:CAS745-65-3-ARRB1-RAF1-MAP2K1-MAP2K2-MAPK3-MAPK1)
→
RAF1
(modification, collaborate)
-
BioCarta role of ß-arrestins in the activation and targeting of map kinases:
Ligand/GPCR(+)/Arrestin/RAF1/MEK1/MEK2/ERK1/ERK2 complex (CCL4_EDN1__AGT_CCL11_CXCL12_F2_compound:CAS66575-29-9_compound:CAS745-65-3-ARRB1-RAF1-MAP2K1-MAP2K2-MAPK3-MAPK1)
→
ERK2 (MAPK1)
(modification, collaborate)
-
BioCarta role of ß-arrestins in the activation and targeting of map kinases:
Ligand/GPCR(+)/Arrestin/RAF1/MEK1/MEK2/ERK1/ERK2 complex (CCL4_EDN1__AGT_CCL11_CXCL12_F2_compound:CAS66575-29-9_compound:CAS745-65-3-ARRB1-RAF1-MAP2K1-MAP2K2-MAPK3-MAPK1)
→
Ligand/GPCR(+)/Arrestin complex (CCL4_EDN1__AGT_CCL11_CXCL12_F2_compound:CAS66575-29-9_compound:CAS745-65-3-ARRB1)
(modification, collaborate)
-
BioCarta role of ß-arrestins in the activation and targeting of map kinases:
Ligand/GPCR(+)/Arrestin/RAF1/MEK1/MEK2/ERK1/ERK2 complex (CCL4_EDN1__AGT_CCL11_CXCL12_F2_compound:CAS66575-29-9_compound:CAS745-65-3-ARRB1-RAF1-MAP2K1-MAP2K2-MAPK3-MAPK1)
→
MEK1 (MAP2K1)
(modification, collaborate)
-
BioCarta role of ß-arrestins in the activation and targeting of map kinases:
Ligand/GPCR(+)/Arrestin/RAF1/MEK1/MEK2/ERK1/ERK2 complex (CCL4_EDN1__AGT_CCL11_CXCL12_F2_compound:CAS66575-29-9_compound:CAS745-65-3-ARRB1-RAF1-MAP2K1-MAP2K2-MAPK3-MAPK1)
→
ERK1 (MAPK3)
(modification, collaborate)
-
BioCarta role of ß-arrestins in the activation and targeting of map kinases:
Ligand/GPCR(+)/Arrestin complex (CCL4_EDN1__AGT_CCL11_CXCL12_F2_compound:CAS66575-29-9_compound:CAS745-65-3-ARRB1)
→
ERK1 (MAPK3)
(modification, collaborate)
-
BioCarta role of ß-arrestins in the activation and targeting of map kinases:
Ligand/GPCR(+)/Arrestin/RAF1/MEK1/MEK2/ERK1/ERK2 complex (CCL4_EDN1__AGT_CCL11_CXCL12_F2_compound:CAS66575-29-9_compound:CAS745-65-3-ARRB1-RAF1-MAP2K1-MAP2K2-MAPK3-MAPK1)
→
dynamin gtpase (DNM1)
(translocation, collaborate)
-
BioCarta role of ß-arrestins in the activation and targeting of map kinases:
Ligand/GPCR(+)/Arrestin/RAF1/MEK1/MEK2/ERK1/ERK2 complex (CCL4_EDN1__AGT_CCL11_CXCL12_F2_compound:CAS66575-29-9_compound:CAS745-65-3-ARRB1-RAF1-MAP2K1-MAP2K2-MAPK3-MAPK1)
→
Ligand/GPCR(+)/Arrestin/RAF1/MEK1/MEK2/ERK1/ERK2(cy) complex (CCL4_EDN1__AGT_CCL11_CXCL12_F2_compound:CAS66575-29-9_compound:CAS745-65-3-ARRB1-RAF1-MAP2K1-MAP2K2-MAPK3-MAPK1)
(translocation, collaborate)
-
BioCarta role of ß-arrestins in the activation and targeting of map kinases:
dynamin gtpase (DNM1)
→
Ligand/GPCR(+)/Arrestin/RAF1/MEK1/MEK2/ERK1/ERK2(cy) complex (CCL4_EDN1__AGT_CCL11_CXCL12_F2_compound:CAS66575-29-9_compound:CAS745-65-3-ARRB1-RAF1-MAP2K1-MAP2K2-MAPK3-MAPK1)
(translocation, activates)
Text-mined interactions from Literome
Portela et al., Biol Reprod 2011
:
The addition of selective AGT-2 antagonists to cells stimulated with LH plus AGT-2 demonstrated that
AGT-2 did not act through the type 1 receptor and did not
increase mitogen activated protein kinase 3/1 phosphorylation
Abdo et al., Diabetologia 2013
:
In vitro, insulin
inhibited Agt but stimulated Hnrnpf and Hnrnpk expression in high-glucose media via p44/42
mitogen activated protein kinase signalling in RPTCs. Transfection with Hnrnpf or Hnrnpk small interfering RNAs prevented insulin inhibition of Agt expression in RPTCs